In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addrenex Pharmaceuticals Inc.

Division of Shionogi & Co. Ltd.
www.addrenex.com

Latest From Addrenex Pharmaceuticals Inc.

VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back

Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?

Companies Business Strategies

Acorda completes Neuronex acquisition as diazepam nasal spray nears NDA

Acorda Therapeutics paid $6.8 million on 20 December to complete the acquisition of Neuronex and the Ardsley, New York-based company will make up to $134 million in additional milestone payments plus royalties for Neuronex's patient-friendly intranasal formulation of diazepam for the control of acute repetitive seizures (ARS).

Neurology Immune Disorders

Shionogi In-licenses Shire ADHD Drugs In Untapped Japanese Market

Severe disappointment in U.S. performance has Shionogi looking back home, where ADHD has high growth potential as well as high hurdles.

BioPharmaceutical Japan

Shionogi In-licenses Shire ADHD Drugs In Untapped Japanese Market

Severe disappointment in U.S. performance has Shionogi looking back home, where ADHD has high growth potential as well as high hurdles.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Shionogi & Co. Ltd.
  • Senior Management
  • Moise Khayrallah, PhD, CEO
    Karen J Adams, Acting CFO
  • Contact Info
  • Addrenex Pharmaceuticals Inc.
    Phone: (919) 941-0800
    4825 Creekstone Dr.
    Ste. 100
    Durham, NC 27703-8051
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register